APA aipamena

Simonsen, C. S., Flemmen, H. Ø., Broch, L., Brunborg, C., Berg-Hansen, P., Moen, S. M., & Celius, E. G. (2021). Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry. Front Neurol.

Chicago Style aipamena

Simonsen, Cecilia Smith, Heidi Øyen Flemmen, Line Broch, Cathrine Brunborg, Pål Berg-Hansen, Stine Marit Moen, and Elisabeth Gulowsen Celius. "Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry." Front Neurol 2021.

MLA aipamena

Simonsen, Cecilia Smith, et al. "Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry." Front Neurol 2021.